Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Peter_Salzmann
|
| gptkbp:clinicalTrialPhase |
gptkb:myasthenia_gravis
Graves' disease thyroid eye disease warm autoimmune hemolytic anemia |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:IMVT-1402
gptkb:batoclimab |
| gptkbp:focusesOn |
immunology
autoimmune diseases |
| gptkbp:foundedYear |
2018
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunovant, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
approximately 100 (2023)
|
| gptkbp:parentCompany |
gptkb:Roivant_Sciences
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
FcRn inhibition
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:IMVT
|
| gptkbp:website |
https://immunovant.com
|
| gptkbp:bfsParent |
gptkb:IMVT
|
| gptkbp:bfsLayer |
7
|